{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T23:30:55Z","timestamp":1787959855831,"version":"build-2784847793"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Our study aimed to determine if chemotherapy administration based on the 21-gene Oncotype DX Recurrence Score (RS) in men with hormone receptor positive (HR+) Her2 negative (Her2-) lymph node positive(LN+) breast cancers (BC) impacted overall survival (OS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>We conducted a retrospective cohort study on adult men and women with HR+ Her2-, 1\u20133 axillary LN\u2009+\u2009BC, with a valid oncotype DX RS assay, diagnosed between the years 2004\u20132020, using the National Cancer Database. RS risk categories were defined as low risk: 0\u201313, intermediate risk:14\u201325, and high risk: \u226526.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of the 77,820 patients included in the study, 900 (1.2%) were male and 76,920 (98.8%) were female. Higher RS (both as a continuous and categorical variable) was significantly associated with worse OS in males (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.003 continuous,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.006 categorical), females\u2009\u2264\u200950\u2009years old and females\u2009&gt;\u200950\u2009years old (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001 both continuous and categorical, in both groups). In the stratified adjusted models, there was no association between receipt of chemotherapy and OS in males for all RS risk groups. Conversely, chemotherapy improved OS for women\u2009\u2264\u200950 and for women\u2009&gt;\u200950 who belonged to the intermediate and high RS risk groups (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001 and\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001 respectively (women\u2009\u2264\u200950);\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.005 and\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090\u00b7001\u00a0respectively (women\u2009&gt;\u200950)).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>RS as determined by the Oncotype DX assay is associated with OS in men and women with HR+ Her2- LN+ BC. However, RS is not an indicator of the benefit of chemotherapy on OS in men, in contrast to women, with HR+ Her2- LN+ BC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10549-026-07978-6","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T08:20:32Z","timestamp":1779265232000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The applicability of the 21-gene assay to inform chemotherapy benefit in lymph node positive hormone receptor positive male breast cancer"],"prefix":"10.1007","volume":"217","author":[{"given":"Anu G.","family":"Gaba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca J.","family":"Renfrew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"issue":"27","key":"7978_CR1","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1056\/NEJMoa041588","volume":"351","author":"S Paik","year":"2004","unstructured":"Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N (2004 Dec 30) A multigene assay to predict Recurrence of tamoxifen-Treated, node-negative breast cancer. N Engl J Med 351(27):2817\u20132826. https:\/\/doi.org\/10.1056\/NEJMoa041588.","journal-title":"N Engl J Med"},{"issue":"2","key":"7978_CR2","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1804710","volume":"379","author":"JA Sparano","year":"2018","unstructured":"Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE, Dees EC, Goetz MP, Olson JA, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin PM, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge GW (2018 Jul 12) Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med 379(2):111\u2013121. https:\/\/doi.org\/10.1056\/NEJMoa1804710.","journal-title":"N Engl J Med"},{"issue":"23","key":"7978_CR3","doi-asserted-by":"publisher","first-page":"3726","DOI":"10.1200\/JCO.2005.04.7985","volume":"24","author":"S Paik","year":"2006","unstructured":"Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, Cronin M, Baehner FL, Watson D, Bryant J, Costantino JP, Geyer CE, Wickerham DL, Wolmark N (2006 Aug 10) Gene expression and benefit of chemotherapy in women with node-negative, Estrogen receptor\u2013positive breast cancer. JCO 24(23):3726\u20133734. https:\/\/doi.org\/10.1200\/JCO.2005.04.7985.","journal-title":"JCO"},{"issue":"1","key":"7978_CR4","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S1470-2045(09)70314-6","volume":"11","author":"KS Albain","year":"2010","unstructured":"Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh IT, Ravdin P, Bugarini R, Baehner FL, Davidson NE, Sledge GW, Winer EP, Hudis C, Ingle JN, Perez EA, Pritchard KI, Shepherd L, Gralow JR, Yoshizawa C, Allred DC, Osborne CK, Hayes DF (2010 Jan) Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. The Lancet Oncol 11(1):55\u201365. https:\/\/doi.org\/10.1016\/S1470-2045(09)70314-6.","journal-title":"The Lancet Oncol"},{"issue":"25","key":"7978_CR5","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1056\/NEJMoa2108873","volume":"385","author":"K Kalinsky","year":"2021","unstructured":"Kalinsky K, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, Lin NU, Perez EA, Goldstein LJ, Chia SKL, Dhesy-Thind S, Rastogi P, Alba E, Delaloge S, Martin M, Kelly CM, Ruiz-Borrego M, Gil-Gil M, Arce-Salinas CH, Brain EGC, Lee E-S, Pierga J-Y, Bermejo B, Ramos-Vazquez M, Jung K-H, Ferrero J-M, Schott AF, Shak S, Sharma P, Lew DL, Miao J, Tripathy D, Pusztai L, Hortobagyi GN (2021 Dec 16) 21-gene assay to inform chemotherapy benefit in node-positive breast cancer. N Engl J Med 385(25):2336\u20132347. https:\/\/doi.org\/10.1056\/NEJMoa2108873.","journal-title":"N Engl J Med"},{"key":"7978_CR6","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.critrevonc.2016.02.017","volume":"101","author":"IS Fentiman","year":"2016","unstructured":"Fentiman IS (2016 May) Male breast cancer is not congruent with the female disease. Crit Rev Oncol\/Hematol 101:119\u2013124. https:\/\/doi.org\/10.1016\/j.critrevonc.2016.02.017.","journal-title":"Crit Rev Oncol\/Hematol"},{"key":"7978_CR7","doi-asserted-by":"publisher","unstructured":"Massarweh SA, Sledge GW, Miller DP, McCullough D, Petkov VI, Shak S (2018 May 10) Molecular characterization and mortality from breast cancer in men. JCO 36(14):1396\u20131404. https:\/\/doi.org\/10.1200\/JCO.2017.76.8861.","DOI":"10.1200\/JCO.2017.76.8861"},{"issue":"1","key":"7978_CR8","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1158\/1078-0432.CCR-19-2424","volume":"26","author":"F Wang","year":"2020","unstructured":"Wang F, Reid S, Zheng W, Pal T, Meszoely I, Mayer IA, Bailey CE, Park BH, Shu X-O (2020 Jan 1) Sex disparity observed for Oncotype DX breast Recurrence Score in predicting mortality among patients with early Stage ER-Positive breast cancer. Clin Cancer Res 26(1):101\u2013109. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-2424.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"7978_CR9","doi-asserted-by":"publisher","first-page":"5546","DOI":"10.1245\/s10434-024-15393-8","volume":"31","author":"BE Palis","year":"2024","unstructured":"Palis BE, Janczewski LM, Browner AE, Cotler J, Nogueira L, Richardson LC, Benard V, Wilson RJ, Walker N, McCabe RM, Boffa DJ, Nelson H (2024 Sep) The National cancer Database conforms to the standardized framework for registry and data quality. Ann Surg Oncol 31(9):5546\u20135559. https:\/\/doi.org\/10.1245\/s10434-024-15393-8.","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"7978_CR10","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1245\/s10434-018-6566-7","volume":"25","author":"AM Altman","year":"2018","unstructured":"Altman AM, Kizy S, Yuan J, Denbo JW, Jensen EH, Hui JYC, Tuttle TM, Marmor S (2018 Aug) Distribution of 21-gene Recurrence scores in male breast cancer in the United States. Ann Surg Oncol 25(8):2296\u20132302. https:\/\/doi.org\/10.1245\/s10434-018-6566-7.","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"7978_CR11","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s10549-016-4085-4","volume":"161","author":"M Pritzlaff","year":"2017","unstructured":"Pritzlaff M, Summerour P, McFarland R, Li S, Reineke P, Dolinsky JS, Goldgar DE, Shimelis H, Couch FJ, Chao EC, LaDuca H (2017 Feb) Male breast cancer in a multi-gene panel testing cohort: insights and unexpected results. Breast Cancer Res Treat 161(3):575\u2013586. https:\/\/doi.org\/10.1007\/s10549-016-4085-4.","journal-title":"Breast Cancer Res Treat"},{"key":"7978_CR12","doi-asserted-by":"publisher","unstructured":"Rizzolo P, Silvestri V, Tommasi S, Pinto R, Danza K, Falchetti M, Gulino M, Frati P, Ottini L (2013 Nov) Male breast cancer: genetics, epigenetics, and ethical aspects. Ann Oncol 24:viii75\u201382. https:\/\/doi.org\/10.1093\/annonc\/mdt316.","DOI":"10.1093\/annonc\/mdt316"},{"issue":"2","key":"7978_CR13","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1002\/ijc.32106","volume":"145","author":"P Rizzolo","year":"2019","unstructured":"Rizzolo P, Zelli V, Silvestri V, Valentini V, Zanna I, Bianchi S, Masala G, Spinelli AM, Tibiletti MG, Russo A, Varesco L, Giannini G, Capalbo C, Calistri D, Cortesi L, Viel A, Bonanni B, Azzollini J, Manoukian S, Montagna M, Peterlongo P, Radice P, Palli D, Ottini L (2019 Jul 15) Insight into genetic susceptibility to male breast cancer by multigene panel testing: results from a multicenter study in Italy. Intl J Cancer 145(2):390\u2013400. https:\/\/doi.org\/10.1002\/ijc.32106.","journal-title":"Intl J Cancer"},{"key":"7978_CR14","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.ejca.2023.04.022","volume":"188","author":"A Bucalo","year":"2023","unstructured":"Bucalo A, Conti G, Valentini V, Capalbo C, Bruselles A, Tartaglia M, Bonanni B, Calistri D, Coppa A, Cortesi L, Giannini G, Gismondi V, Manoukian S, Manzella L, Montagna M, Peterlongo P, Radice P, Russo A, Tibiletti MG, Turchetti D, Viel A, Zanna I, Palli D, Silvestri V, Ottini L (2023 Jul) Male breast cancer risk associated with pathogenic variants in genes other than BRCA1\/2: an Italian case-control study. Eur J Criminol Cancer 188:183\u2013191. https:\/\/doi.org\/10.1016\/j.ejca.2023.04.022.","journal-title":"Eur J Criminol Cancer"},{"issue":"1","key":"7978_CR15","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/his.12862","volume":"68","author":"S Deb","year":"2016","unstructured":"Deb S, Lakhani SR, Ottini L, Fox SB (2016 Jan) The cancer genetics and pathology of male breast cancer. Histopathology 68(1):110\u2013118. https:\/\/doi.org\/10.1111\/his.12862.","journal-title":"Histopathology"},{"issue":"3","key":"7978_CR16","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1002\/cam4.4469","volume":"11","author":"W Fang","year":"2022","unstructured":"Fang W, Huang Y, Han X, Peng J, Zheng M (2022 Feb) Characteristics of metastasis and survival between male and female breast cancer with different molecular subtypes: a population-based observational study. Cancer Med 11(3):764\u2013777. https:\/\/doi.org\/10.1002\/cam4.4469.","journal-title":"Cancer Med"},{"issue":"11","key":"7978_CR17","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1200\/JCO.2009.24.4798","volume":"28","author":"M Dowsett","year":"2010","unstructured":"Dowsett M, Cuzick J, Wale C, Forbes J, Mallon EA, Salter J, Quinn E, Dunbier A, Baum M, Buzdar A, Howell A, Bugarini R, Baehner FL, Shak S (2010 Apr 10) Prediction of risk of distant Recurrence using the 21-gene Recurrence Score in node-negative and node-positive postmenopausal patients with breast cancer Treated with anastrozole or tamoxifen: a TransATAC study. JCO 28(11):1829\u20131834. https:\/\/doi.org\/10.1200\/JCO.2009.24.4798.","journal-title":"JCO"},{"issue":"10","key":"7978_CR18","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1200\/JCO.2009.23.7610","volume":"28","author":"EP Mamounas","year":"2010","unstructured":"Mamounas EP, Tang G, Fisher B, Paik S, Shak S, Costantino JP, Watson D, Geyer CE, Wickerham DL, Wolmark N (2010 Apr 1) Association between the 21-gene Recurrence Score assay and risk of locoregional Recurrence in node-negative, Estrogen receptor\u2013positive breast cancer: results from NSABP B-14 and NSABP B-20. JCO 28(10):1677\u20131683. https:\/\/doi.org\/10.1200\/JCO.2009.23.7610.","journal-title":"JCO"},{"key":"7978_CR19","doi-asserted-by":"publisher","first-page":"175883592095835","DOI":"10.1177\/1758835920958358","volume":"12","author":"WP Li","year":"2020","unstructured":"Li WP, Gao HF, Ji F, Zhu T, Cheng MY, Yang M, Yang C-Q, Zhang L-L, Li J-Q, Zhang J-S, Wang K (2020 Jan) The role of adjuvant chemotherapy in stage I\u2013III male breast cancer: a SEER-based analysis. Ther Adv Med Oncol 12:1758835920958358. https:\/\/doi.org\/10.1177\/1758835920958358.","journal-title":"Ther Adv Med Oncol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-07978-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-026-07978-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-07978-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T08:29:48Z","timestamp":1784017788000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-026-07978-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["7978"],"URL":"https:\/\/doi.org\/10.1007\/s10549-026-07978-6","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]},"assertion":[{"value":"26 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"36"}}